Advanced Proteome Therapeutics Corporation
Advanced Proteome Therapeutics Corporation, through its subsidiary, Advanced Proteome Therapeutics Inc., operates as a biotechnology company in the United States. The company develops and commercializes a platform for the chemical modification of protein therapeutics. Its platform is dedicated to applications in the field of antibody drug conjugates, as well as focused on protein conjugates and i… Read more
Advanced Proteome Therapeutics Corporation (APTCF) - Total Assets
Latest total assets as of April 2023: $62.75K USD
Based on the latest financial reports, Advanced Proteome Therapeutics Corporation (APTCF) holds total assets worth $62.75K USD as of April 2023.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Advanced Proteome Therapeutics Corporation - Total Assets Trend (1997–2022)
This chart illustrates how Advanced Proteome Therapeutics Corporation’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Advanced Proteome Therapeutics Corporation - Asset Composition Analysis
Current Asset Composition (July 2022)
Advanced Proteome Therapeutics Corporation's total assets of $62.75K consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 85.6% |
| Accounts Receivable | $49.76K | 7.8% |
| Inventory | $-23.00 | 0.0% |
| Property, Plant & Equipment | $15.54K | 2.4% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1997–2022)
This chart illustrates how Advanced Proteome Therapeutics Corporation's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Advanced Proteome Therapeutics Corporation's current assets represent 97.6% of total assets in 2022, an increase from 81.7% in 1997.
- Cash Position: Cash and equivalents constituted 85.6% of total assets in 2022, up from 11.3% in 1997.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 1997.
- Asset Diversification: The largest asset category is accounts receivable at 7.8% of total assets.
Advanced Proteome Therapeutics Corporation Competitors by Total Assets
Key competitors of Advanced Proteome Therapeutics Corporation based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Advanced Proteome Therapeutics Corporation - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Advanced Proteome Therapeutics Corporation generates 0.00x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Excellent ROA - For every $100 in assets, Advanced Proteome Therapeutics Corporation generates $ 119.36 in net profit.
Advanced Proteome Therapeutics Corporation - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.73 | 0.55 | 0.26 |
| Quick Ratio | 0.89 | 0.55 | 0.26 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-22.87K | $ -693.50K | $ -496.11K |
Advanced Proteome Therapeutics Corporation - Advanced Valuation Insights
This section examines the relationship between Advanced Proteome Therapeutics Corporation's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.22 |
| Latest Market Cap to Assets Ratio | 0.01 |
| Asset Growth Rate (YoY) | -29.1% |
| Total Assets | $636.41K |
| Market Capitalization | $7.43K USD |
Valuation Analysis
Below Book Valuation: The market values Advanced Proteome Therapeutics Corporation's assets below their book value (0.01 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Advanced Proteome Therapeutics Corporation's assets decreased by 29.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Advanced Proteome Therapeutics Corporation (1997–2022)
The table below shows the annual total assets of Advanced Proteome Therapeutics Corporation from 1997 to 2022.
| Year | Total Assets | Change |
|---|---|---|
| 2022-07-31 | $636.41K | -29.11% |
| 2021-07-31 | $897.71K | +4371.55% |
| 2020-07-31 | $20.08K | -87.98% |
| 2019-07-31 | $166.99K | -9.07% |
| 2018-07-31 | $183.64K | +1.99% |
| 2017-07-31 | $180.06K | +47.90% |
| 2016-07-31 | $121.75K | -83.30% |
| 2015-07-31 | $728.92K | -15.00% |
| 2014-07-31 | $857.54K | +285.65% |
| 2013-07-31 | $222.36K | +49.37% |
| 2012-07-31 | $148.87K | -62.14% |
| 2011-07-31 | $393.24K | -28.57% |
| 2010-07-31 | $550.55K | -64.42% |
| 2009-07-31 | $1.55 Million | -40.46% |
| 2008-07-31 | $2.60 Million | +60.78% |
| 2007-07-31 | $1.62 Million | -- |
| 2006-07-31 | $0.00 | -- |
| 2005-07-31 | $196.14K | -73.15% |
| 2004-07-31 | $730.59K | -12.64% |
| 2003-07-31 | $836.26K | -58.10% |
| 2002-07-31 | $2.00 Million | -63.37% |
| 2001-07-31 | $5.45 Million | -35.68% |
| 2000-07-31 | $8.47 Million | -28.80% |
| 1999-07-31 | $11.90 Million | -25.68% |
| 1998-07-31 | $16.01 Million | +210.79% |
| 1997-07-31 | $5.15 Million | -- |